Ionis Pharmaceuticals Drops Another After Phase 3 Setback
Ionis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
Overview of beginner-friendly HYSA options, focusing on accessibility, straightforward terms, and competitive rates.
24,631 articlesIonis Pharmaceuticals dropped again after a Phase 3 failure in transthyretin amyloid cardiomyopathy, triggering a bro...
AMD is positioning itself as a robust player across consumer, data center, and AI markets. This article breaks down w...
NVIDIA just revealed owns a notable minority stake in Nebius, triggering a sharp stock move. This article breaks down...
Electricity demand is rising fast, and this shifts the playing field for energy stocks. Learn how to identify what be...
A large insider stake in Veris Residential stock signals conviction from an established manager. This article explain...
The Meta deal lights up new questions about AMD's growth path and dilution risk. This guide breaks down what the 6 gi...
After a slow stretch for home sales, many buyers and investors wonder if 2026 will flip the script. This guide breaks...
A fresh examination of the innovations powering U.S. military dominance and how investors are pricing defense names i...
Markets are unsettled, but long-term investors can find value. This guide highlights three AI leaders that are curren...
As Lumentum and Coherent rally, Onto Innovation could be the next optics supplier to gain. Analysts say the surge ref...
Traders are loading into a high-stakes energy bet nicknamed NACHO as JPMorgan warns of June shortages. The move rippl...
Hidden in plain sight, this under-the-radar nuclear energy stock offers a blend of reliable cash flow and growth pote...